Minimal important differences for fatigue patient reported outcome measures—a systematic review

BackgroundFatigue is the most frequent symptom reported by patients with chronic illnesses. As a subjective experience, fatigue is commonly assessed with patient-reported outcome measures (PROMs). Currently, there are more than 40 generic and disease-specific PROMs for assessing fatigue in use today. The interpretation of changes in PROM scores may be enhanced by estimates of the so-called minimal important difference (MID). MIDs are not fixed attributes of PROMs but rather vary in relation to estimation method, clinical and demographic characteristics of the study group, etc. The purpose of this paper is to compile published MIDs for fatigue PROMs, spanning diagnostic/patient groups and estimation methods, and to provide information relevant for appraising their appropriateness for use in specific clinical trials and in monitoring fatigue in defined patient groups in routine clinical practice.MethodsA systematic search of three databases (Scopus, CINAHL and Cochrane) for studies published between January 2000 to April 2015 using fatigue and variations of the term MID, e.g. MCID, MIC, etc. Two authors screened search hits and extracted data independently. Data regarding MIDs, anchors used and study designs were compiled in tables.ResultsIncluded studies (n = 41) reported 60 studies or substudies estimating MID for 28 fatigue scales, subscales or single item measures in a variety of diagnostic groups and study designs. All studies used anchor-based methods, 21/60 measures also included distribution-based methods and 17/60 used triangulation of methods. Both similarities and dissimilarities were seen within the MIDs.ConclusionsMagnitudes of published MIDs for fatigue PROMs vary considerably. Information about the derivation of fatigue MIDs is needed to evaluate their applicability and suitability for use in clinical practice and research.

[1]  G. Bleijenberg,et al.  Dimensional assessment of chronic fatigue syndrome. , 1994, Journal of psychosomatic research.

[2]  D. Cella,et al.  Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. , 2011, Journal of clinical epidemiology.

[3]  D. Osoba,et al.  Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials , 2011, Supportive Care in Cancer.

[4]  C. Terwee,et al.  Mind the MIC: large variation among populations and methods. , 2010, Journal of clinical epidemiology.

[5]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.

[6]  D. Cella,et al.  Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial. , 2009, Current medical research and opinion.

[7]  R. Hays,et al.  Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment , 2005, Hepatology.

[8]  D. Osoba,et al.  Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Mody,et al.  Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference , 2007, Current medical research and opinion.

[10]  P. Gascón,et al.  Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer , 2010, Supportive Care in Cancer.

[11]  V. Joish,et al.  Validation of the sleep impact scale in patients with major depressive disorder and insomnia , 2009, Current medical research and opinion.

[12]  R. Hays,et al.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. , 2008, Journal of clinical epidemiology.

[13]  A. Tennant,et al.  Perceived changes and minimum clinically important difference of the Neurological Fatigue Index for multiple sclerosis (NFI-MS) , 2013, Multiple sclerosis.

[14]  J. Ware,et al.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[15]  D. Cella,et al.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[16]  N. Santanello,et al.  Interpreting and reporting results based on patient-reported outcomes. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  J. Pope,et al.  The Minimally Important Difference for Patient-reported Outcomes in Spondyloarthropathies including Pain, Fatigue, Sleep, and Health Assessment Questionnaire , 2010, The Journal of Rheumatology.

[18]  W. Tierney,et al.  Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease , 2003, Journal of General Internal Medicine.

[19]  L. Doward,et al.  Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS) , 2010, Health and quality of life outcomes.

[20]  J. Beaumont,et al.  Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in Patients with Moderately to Severely Active Systemic Lupus Erythematosus, Participating in a Clinical Trial , 2011, The Journal of Rheumatology.

[21]  A. Richardson,et al.  Fatigue: a concept analysis. , 1996, International journal of nursing studies.

[22]  E. Bruera,et al.  Clinically important improvement in the intensity of fatigue in patients with advanced cancer. , 2007, Journal of palliative medicine.

[23]  L. Matza,et al.  The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition , 2012, Quality of Life Research.

[24]  Liying Zhang,et al.  An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases , 2012, Supportive Care in Cancer.

[25]  A. Wu,et al.  Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences , 2009 .

[26]  M. King A point of minimal important difference (MID): a critique of terminology and methods , 2011, Expert review of pharmacoeconomics & outcomes research.

[27]  J. Spertus,et al.  Clinically important differences in health status for patients with heart disease: an expert consensus panel report. , 2004, American heart journal.

[28]  J. Pope,et al.  The minimally important difference (MID) for patient-reported outcomes including pain, fatigue, sleep and the health assessment questionnaire disability index (HAQ-DI) in primary Sjögren's syndrome. , 2011, Clinical and experimental rheumatology.

[29]  J. Kopec,et al.  Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. , 2008, Journal of clinical epidemiology.

[30]  R. Kane The clinical significance of statistical significance. , 2008, The oncologist.

[31]  G. Guyatt,et al.  The minimal detectable change cannot reliably replace the minimal important difference. , 2010, Journal of clinical epidemiology.

[32]  G. Guyatt,et al.  Measurement Properties and Interpretability of the Chronic Respiratory Disease Questionnaire (CRQ) , 2005, COPD.

[33]  L. Nail,et al.  Measurement of fatigue: Determining minimally important clinical differences , 2002 .

[34]  J. Cramer,et al.  Defining minimally important change in QOLIE-31 scores: Estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures , 2012, Epilepsy & Behavior.

[35]  P. Fayers,et al.  Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma , 2010, Health and quality of life outcomes.

[36]  G. R. Williams,et al.  An integrated method to determine meaningful changes in health-related quality of life. , 2004, Journal of clinical epidemiology.

[37]  A. Wu,et al.  Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. , 2009, Current medical research and opinion.

[38]  Ross D Crosby,et al.  Defining clinically meaningful change in health-related quality of life. , 2003, Journal of clinical epidemiology.

[39]  M. Baron,et al.  The Minimally Important Difference in Clinical Practice for Patient-centered Outcomes Including Health Assessment Questionnaire, Fatigue, Pain, Sleep, Global Visual Analog Scale, and SF-36 in Scleroderma , 2010, The Journal of Rheumatology.

[40]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[41]  R. Hays,et al.  Approaches and Recommendations for Estimating Minimally Important Differences for Health-Related Quality of Life Measures , 2005, COPD.

[42]  Liying Zhang,et al.  Minimal important differences in the EORTC QLQ‐C15‐PAL to determine meaningful change in palliative advanced cancer patients , 2016, Asia-Pacific journal of clinical oncology.

[43]  D. Patrick,et al.  Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. , 2003, European journal of cancer.

[44]  M. Ward,et al.  Domain-specific transition questions demonstrated higher validity than global transition questions as anchors for clinically important improvement. , 2015, Journal of clinical epidemiology.

[45]  J. Browne,et al.  The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research , 2014, BMJ quality & safety.

[46]  J. de Vries,et al.  Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. , 2011, Respiratory medicine.

[47]  L. Nail,et al.  Fatigue and the cancer experience: the state of the knowledge. , 1994, Oncology nursing forum.

[48]  D. Revicki,et al.  Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[49]  Liying Zhang,et al.  Minimal important differences in the EORTC QLQ‐C30 in patients with advanced cancer , 2014, Asia-Pacific journal of clinical oncology.

[50]  L. Whitehead,et al.  The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. , 2009, Journal of pain and symptom management.

[51]  D. Beaton,et al.  Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. , 2002, Current opinion in rheumatology.

[52]  P. Tugwell,et al.  Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[53]  Liying Zhang,et al.  Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. , 2013, Journal of pain and symptom management.

[54]  R. Hays,et al.  The Minimally Important Difference for the Fatigue Visual Analog Scale in Patients with Rheumatoid Arthritis Followed in an Academic Clinical Practice , 2008, The Journal of Rheumatology.

[55]  A. Copay,et al.  Understanding the minimum clinically important difference: a review of concepts and methods. , 2007, The spine journal : official journal of the North American Spine Society.

[56]  J. Fisk,et al.  A novel approach to estimate the minimally important difference for the fatigue impact scale in multiple sclerosis patients , 2010, Quality of Life Research.

[57]  J. Fisk,et al.  The Impact of Fatigue on Patients with Multiple Sclerosis , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[58]  J. Kopec,et al.  Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[59]  Alexis Wright,et al.  Clinimetrics corner: a closer look at the minimal clinically important difference (MCID) , 2012, The Journal of manual & manipulative therapy.

[60]  J. Fleming,et al.  Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population , 2010, Supportive Care in Cancer.

[61]  J. Pope,et al.  The Minimally Important Difference for Patient Reported Outcomes in Systemic Lupus Erythematosus Including the HAQ-DI, Pain, Fatigue, and SF-36 , 2009, The Journal of Rheumatology.

[62]  S. McKenna Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science , 2011, BMC medicine.

[63]  L. Krupp,et al.  A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. , 1993, The Journal of neuropsychiatry and clinical neurosciences.

[64]  J. Pope,et al.  Minimally Important Difference for Patient-reported Outcomes in Psoriatic Arthritis: Health Assessment Questionnaire and Pain, Fatigue, and Global Visual Analog Scales , 2010, The Journal of Rheumatology.

[65]  D. Cella,et al.  Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening , 2002, Quality of Life Research.

[66]  W. Tierney,et al.  Triangulating patient and clinician perspectives on clinically important differences in health-related quality of life among patients with heart disease. , 2007, Health services research.